The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer
Open Access
- 4 June 2007
- Vol. 109 (12) , 2410-2419
- https://doi.org/10.1002/cncr.22726
Abstract
BACKGROUND.: It is unclear how noncancer conditions affect the use or effectiveness of adjuvant therapy among older patients with colon cancer.METHODS.: The authors conducted a cohort study of older patients with stage III colon cancer who were diagnosed from 1993 to 1999 in the Surveillance, Epidemiology, and End Results‐Medicare database. The correlations between receipt of adjuvant chemotherapy and heart failure, diabetes, and chronic obstructive pulmonary disease (COPD) were assessed. Multivariable regression analysis was used to assess the risk of death and hospitalization as a function of treatment and comorbidity status.RESULTS.: The study sample consisted of 5330 patients (median age, 76 years). The use of adjuvant therapy was related significantly to heart failure (36.2% vs 64.9% of patients with vs without heart failure, respectively; adjusted odds ratio [OR], 0.49; 95% confidence interval [95% CI], 0.40–0.60). More moderate correlations were observed for COPD (OR, 0.83; 95% CI, 0.70–0.99) and diabetes (OR, 0.81; 95% CI, 0.68–0.97). Among patients who had heart failure, the 5‐year survival was significantly higher among those who received adjuvant chemotherapy (adjusted 5‐year survival rate, 43%; 95% CI, 40–47%) than among those who did not receive adjuvant chemotherapy (30%; 95% CI, 27–34%). Among patients without heart failure, the 5‐year survival estimates among treated and untreated patients were 54% (95% CI, 52–56%) and 41% (95% CI, 38–44%), respectively. The probability of all‐cause, condition‐specific, or toxicity‐related hospitalization associated with adjuvant therapy was not altered by the presence of any of the 3 conditions.CONCLUSIONS.: Although chronic conditions appeared to be a strong barrier to the receipt of adjuvant chemotherapy, adjuvant therapy appeared to provide a significant survival benefit to patients who had colon cancer with the conditions studied. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 37 references indexed in Scilit:
- Multimorbidity and Survival in Older Persons with Colorectal CancerJournal of the American Geriatrics Society, 2006
- Completion of Therapy by Medicare Patients With Stage III Colon CancerJNCI Journal of the National Cancer Institute, 2006
- Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?Journal of Clinical Oncology, 2004
- Measuring Complications of Cancer Treatment Using the SEER-Medicare DataMedical Care, 2002
- Construct Validity of Medicare Chemotherapy ClaimsMedical Care, 2002
- Chemotherapy in the ElderlyNew England Journal of Medicine, 2002
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsNew England Journal of Medicine, 2001
- Cardiotoxicity of the Antiproliferative Compound FluorouracilDrugs, 1999
- Emergency resection and primary anastomosis for left-sided obstructing colorectal carcinoma in the elderlyBritish Journal of Surgery, 1998
- Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancerCancer, 1993